1. Home
  2. MDWD vs SENS Comparison

MDWD vs SENS Comparison

Compare MDWD & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • SENS
  • Stock Information
  • Founded
  • MDWD 2000
  • SENS 1996
  • Country
  • MDWD Israel
  • SENS United States
  • Employees
  • MDWD N/A
  • SENS N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • SENS Industrial Machinery/Components
  • Sector
  • MDWD Health Care
  • SENS Industrials
  • Exchange
  • MDWD Nasdaq
  • SENS Nasdaq
  • Market Cap
  • MDWD 184.8M
  • SENS 179.7M
  • IPO Year
  • MDWD 2014
  • SENS N/A
  • Fundamental
  • Price
  • MDWD $17.75
  • SENS $0.47
  • Analyst Decision
  • MDWD Strong Buy
  • SENS Strong Buy
  • Analyst Count
  • MDWD 1
  • SENS 1
  • Target Price
  • MDWD $25.00
  • SENS $2.00
  • AVG Volume (30 Days)
  • MDWD 56.9K
  • SENS 14.2M
  • Earning Date
  • MDWD 11-26-2024
  • SENS 02-27-2025
  • Dividend Yield
  • MDWD N/A
  • SENS N/A
  • EPS Growth
  • MDWD N/A
  • SENS N/A
  • EPS
  • MDWD N/A
  • SENS N/A
  • Revenue
  • MDWD $19,720,000.00
  • SENS $22,205,000.00
  • Revenue This Year
  • MDWD $10.37
  • SENS $1.05
  • Revenue Next Year
  • MDWD $26.36
  • SENS $61.23
  • P/E Ratio
  • MDWD N/A
  • SENS N/A
  • Revenue Growth
  • MDWD N/A
  • SENS 11.41
  • 52 Week Low
  • MDWD $11.04
  • SENS $0.25
  • 52 Week High
  • MDWD $24.00
  • SENS $0.75
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 53.40
  • SENS 54.88
  • Support Level
  • MDWD $17.33
  • SENS $0.47
  • Resistance Level
  • MDWD $18.25
  • SENS $0.70
  • Average True Range (ATR)
  • MDWD 0.75
  • SENS 0.07
  • MACD
  • MDWD 0.05
  • SENS -0.00
  • Stochastic Oscillator
  • MDWD 73.68
  • SENS 23.56

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.

Share on Social Networks: